US stock · Healthcare sector · Drug Manufacturers—General

Eli Lilly and Company

LLY

NYSE

446.04

USD

+0.38

(+0.09%)

Market Closed

70.85P/E

36Forward P/E

2.90P/E to S&P500

423.414BMarket CAP

0.91%Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

8 Aug

Shares Short

5/31/23

Short % of Float

0.76%

Short % of Shares Outs.

0.63%

% Held by Insiders

0.15%

% Held by Institutions

84.00%

Beta

0.37

PEG Ratio

2.09

52w. high/low

454.95/283.11

Avg. Daily Volume

3.24M

Return %

Stock

S&P 500

1 year

49.05

9.18

3 years

195.16

34.24

5 years

419.07

55.11

Scale: |

High

Low

57.52

28.62

40.78

27.21

38.08

32.02

41.92

33.46

53.99

38.30

58.41

47.53

75.10

50.52

92.85

68.31

85.40

64.18

89.09

73.54

119.84

73.69

137.00

101.36

173.90

117.06

283.90

161.78

375.25

231.87

454.95

309.20

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

17.10

18.62

19.88

20.87

21.80

19.72

20.70

17.66

18.06

19.28

21.74

23.89

23.31

25.65

31.22

31.65

30.31

Earnings per share

2.71

(1.89)

3.94

4.58

3.90

3.57

4.19

2.15

2.18

2.49

(0.19)

3.14

8.69

6.47

6.15

6.93

6.20

FCF per share

3.74

5.80

3.17

5.13

4.97

3.72

4.16

2.52

1.04

3.41

3.28

2.44

3.64

4.67

5.94

5.80

4.14

Dividends per share

1.70

1.88

1.96

1.91

1.90

1.89

1.92

1.96

2.08

2.25

2.52

2.81

3.40

3.92

4.01

CAPEX per share

0.99

0.87

0.78

1.07

1.52

0.91

0.98

1.41

1.47

0.99

2.06

2.94

1.41

2.12

2.07

2.06

2.77

Book Value per sh.

12.54

6.15

8.67

11.23

12.16

12.88

15.79

13.84

13.18

12.72

11.02

9.56

2.72

5.90

9.90

11.81

11.07

Comm.Shares outs.

1,090

1,094

1,098

1,106

1,114

1,146

1,117

1,111

1,105

1,101

1,052

1,028

958

957

907

902

914

Avg. annual P/E ratio

20.4

(24.1)

8.7

7.7

9.4

12.2

12.6

28.7

36.3

30.7

(423.4)

29.7

13.4

22.7

36.4

44.4

70.8

P/E to S&P500

1.2

(1.1)

0.1

0.4

0.6

0.8

0.7

1.6

1.8

1.4

(17.9)

1.2

0.6

1.2

2.1

2.9

Avg. annual div. yield

3.1%

4.1%

5.7%

5.6%

5.3%

4.4%

3.6%

3.1%

2.4%

2.6%

2.5%

2.4%

2.2%

1.9%

1.5%

1.3%

1.1%

Revenue (m)

18,634

20,378

21,836

23,076

24,287

22,603

23,113

19,616

19,959

21,222

22,871

24,556

22,320

24,540

28,318

28,541

27,691

Operating margin

25.8%

27.1%

29.2%

29.3%

22.8%

20.9%

23.2%

13.6%

13.5%

16.3%

9.4%

25.2%

22.3%

24.7%

22.4%

29.0%

25.7%

Depreciation (m)

1,048

1,123

1,298

1,328

1,374

1,462

1,446

1,379

1,428

1,497

1,567

1,609

1,233

1,324

1,548

1,523

1,478

Net profit (m)

2,953

(2,072)

4,329

5,070

4,348

4,089

4,685

2,391

2,408

2,738

(204)

3,232

8,318

6,194

5,582

6,245

5,687

Income tax rate

23.8%

(58.5)%

19.2%

22.3%

18.7%

24.4%

20.5%

20.3%

13.7%

18.9%

109.3%

14.9%

11.9%

14.3%

9.3%

8.3%

9.9%

Net profit margin

15.8%

(10.2)%

19.8%

22.0%

17.9%

18.1%

20.3%

12.2%

12.1%

12.9%

(0.9)%

13.2%

37.3%

25.2%

19.7%

21.9%

20.4%

Working capital (m)

6,989

(656)

5,918

7,739

5,317

4,649

4,188

972

4,344

4,115

4,666

8,662

1,934

4,981

3,400

896

4,801

Long-term debt (m)

4,594

4,616

6,635

6,771

5,465

5,519

4,200

5,368

7,972

8,368

9,941

11,640

13,818

16,587

15,346

14,738

18,881

Equity (m)

13,664

6,735

9,524

12,420

13,542

14,765

17,631

15,373

14,571

14,008

11,592

9,829

2,607

5,642

8,979

10,650

11,190

ROIC

13.7%

(12.9)%

21.7%

21.8%

18.2%

16.2%

18.3%

9.7%

9.3%

10.4%

(0.7)%

11.2%

30.0%

19.1%

17.5%

18.6%

17.2%

Return on capital

14.5%

(4.5)%

20.5%

21.6%

16.4%

16.2%

17.2%

8.5%

8.3%

9.2%

5.4%

9.5%

23.8%

16.3%

13.4%

13.2%

13.4%

Return on equity

21.6%

(30.8)%

45.5%

40.8%

32.1%

27.7%

26.6%

15.5%

16.5%

19.5%

(1.8)%

32.9%

319.1%

109.8%

62.2%

58.6%

50.8%

Plowback ratio

37.2%

199.3%

50.3%

57.3%

49.9%

46.5%

54.7%

12.1%

11.7%

21.2%

1,174.0%

28.5%

71.0%

56.6%

44.7%

43.4%

35.5%

Div.&Repurch./FCF

44.9%

- -

61.8%

38.2%

39.3%

68.3%

82.3%

103.6%

250.9%

73.4%

- -

191.6%

195.5%

71.3%

80.5%

96.3%

116.7%

Capital Structure

27 Apr · 2023 | Q1

All numbers in millions

Total liabilities

$ 41,868

Total assets

$ 53,163

Long-term debt

$ 18,881

Cash and equiv.

$ 3,546

Goodwill

$ 4,073

Retained earnings

$ 10,639

Common stock

903

Enterprise Value

$ 438,748

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

3,681

3,909

2,212

Receivables

6,929

8,127

8,559

Inventory

3,980

3,886

4,310

Other

2,872

2,692

1,364

Current assets

17,462

18,452

18,035

Acc. Payable

1,607

1,671

1,931

Debt due

1,538

1,501

Other

10,866

11,844

13,707

Current liabilities

12,482

15,053

17,138

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

0.79%

4.26%

2.79%

Cash flow

(2.92)%

21.23%

19.83%

Earnings

11.88%

33.46%

(187.97)%

Dividends

14.55%

11.29%

6.00%

Book value

18.61%

30.17%

7.37%

Insider Trading

Type

Date

Rau Diogo

Exempt

6,300

06/01/23

Rau Diogo

InKind

2,848

06/01/23

Rau Diogo

Exempt

6,300

06/01/23

Jonsson Patrik

Sale

6,000

06/01/23

Lilly Endowment Inc

Sale

163,571

05/19/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

6,806

6,740

6,773

8,000

28,318

2022

7,810

6,488

6,942

7,302

28,541

2023

6,960

- -

Earnings per share

Currency: USD

Year

Total

2021

1.49

1.53

1.22

1.90

6.15

2022

2.11

1.06

1.61

2.15

6.93

2023

1.49

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

0.85

3.40

2022

0.98

3.92

2023

1.13

- -

Company Description

Sector:

Healthcare

Industry:

Drug Manufacturers—General

CEO:

Mr. David A. Ricks

Full-time employees:

39,000

City:

Indianapolis

Address:

Lilly Corporate Center

IPO:

Jul 9, 1970

CIK:

0000059478

Website:

lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Powered by AI

Eli Lilly and Company

446.04